Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

That suggests HepaStem could act on the mechanisms of cirrhosis, fibrosis ... rate in these patients is high. NASH is less deadly, particularly in its early stages, but affects a large and ...

Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic ... gold standard for diagnosis of NASH and staging of fibrosis is essential but not sufficient.

The drug, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, did not meet the primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH in the STELLAR-4 ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

In the study, PPAR agonist elafibranor was unable to hit the primary objective of resolving NASH without worsening fibrosis (scarring ... have failed in the latter stages of clinical testing.

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...